 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF said it has secured additional Mitacs funding for preclinical depression studies on its LSD-derivative molecule BETR-001. The Vancouver-based biotechnology firm said in a statement that a joint application to the Mitacs Accelerate program, in collaboration with Dr Argel Aguilar-Valles at Carleton University Department of Neuroscience, was successfully funded for research into the anti-depressant effects and mechanism of action of BETR-001 in preclinical models of depression. 